Yipinhong Pharmaceutical Co Ltd Class A

Yipinhong Pharmaceutical Group announced that its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical received the Drug Registration Certificate for Sertraline Hydrochloride Oral Solution approved and issued by the National Medical Products Administration. The specification is 60 milliliters to 1.2 grams, the registration classification is chemical drug category 3, and the drug approval number is valid until September 1, 2031. The product is a selective serotonin reuptake inhibitor used to treat depression and related symptoms as well as obsessive-compulsive disorder, and is deemed to have passed consistency evaluation. According to Menet data, sertraline sales in Chinese urban and county-level public hospitals reached approximately 804 million yuan in 2025. The company said this approval will further enrich its product pipeline and categories and strengthen the competitiveness of its chronic disease drugs, but cautioned that there is a risk that sales may fall short of expectations.

The clinical trial application for the innovative drug APH03867 tablets, independently developed by Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Yipinhong, has been approved by the National Medical Products Administration, which has agreed to conduct clinical trials for the indication of gout with hyperuricemia.

Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, has received approval from the National Medical Products Administration to conduct clinical trials for its independently developed innovative drug APH04935 tablets, intended for weight control and long-term weight management. The drug is a highly selective small-molecule GLP-1 receptor agonist, classified as a Class 1 innovative chemical drug, and has not been marketed domestically or internationally.

Guangzhou Yipinhong Pharmaceutical Co., Ltd., a wholly owned subsidiary of Yipinhong, has received clinical trial approval from the National Medical Products Administration for its independently developed innovative drug APH04935 tablets. The drug is a highly active, highly selective small-molecule GLP-1R agonist, intended to become a once-daily oral small-molecule GLP-1R agonist for weight control and long-term weight management. The company has received the Drug Clinical Trial Approval Notice and will soon commence clinical trials.

Yipinhong announced that its wholly-owned subsidiary Guangzhou Yipinhong Pharmaceutical's isavuconazonium sulfate for injection and Guangzhou Lianrui Pharmaceutical's perindopril amlodipine tablets (III) have been tentatively selected for the 12th National Centralized Drug Procurement. Isavuconazonium sulfate for injection had sales revenue of zero yuan in 2025, while perindopril amlodipine tablets (III) achieved sales revenue of 3.4817 million yuan, accounting for 0.37% of the company's 2025 operating revenue. In the first quarter of 2026, Yipinhong recorded revenue of 385 million yuan and net profit attributable to the parent of 594 million yuan.

Yipinhong's wholly owned subsidiary, Yipinhong Pharmaceutical, plans to sign a technical service contract with Boji Medical, commissioning it to conduct a clinical study for the innovative drug APH04935 tablets. The total contract value is 6.5 million yuan, tax inclusive. This transaction constitutes a related-party transaction because Yipinhong's independent director Zhang Kejian also serves as a non-independent director of Boji Medical. In the first quarter of 2026, Yipinhong achieved revenue of 385 million yuan and net profit attributable to the parent company of 594 million yuan.

Yipinhong announced that its wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical, has recently obtained the drug registration certificate for Benzbromarone Tablets issued by the National Medical Products Administration. The drug is a chemical drug in Category 3, with a specification of 50 mg, indicated for primary hyperuricemia and the intercritical period of gouty arthritis, and is listed as a Category B product under national medical insurance. According to data from Menet, the sales of benzbromarone in China's urban and county-level public hospitals in 2025 were approximately 269 million yuan. In the first quarter of 2026, Yipinhong achieved revenue of 385 million yuan and net profit attributable to the parent company of 594 million yuan.